{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-24-000106","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.929837+00:00","generated_at":"2026-05-30T03:34:35.766023+00:00","sec_items":["2.02","2.05","5.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Aurinia Q3 net product rev $55.5M (+36% YoY), net income $14.4M; restructuring cuts 45% workforce","bullets":["Q3 total net revenue $67.8M; net product revenue $55.5M (+36% YoY); net income $14.4M vs loss of $13.4M a year ago.","Strategic restructuring: workforce reduction ~45%, expects annual cash savings >$40M, one-time Q4 charge $15-19M.","FY2024 net product revenue guidance reiterated $210-220M; YTD net product revenue $158.6M.","AUR200 Phase 1 first participant dosed; initial results expected H1 2025.","Board: Craig Johnson appointed, Dr. Robert Foster retired (not due to disagreement)."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-24-000106","json":"https://secwatch.observer/filing/0001600620-24-000106.json","markdown":"https://secwatch.observer/filing/0001600620-24-000106.md","text":"https://secwatch.observer/filing/0001600620-24-000106.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000106/0001600620-24-000106-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000106/auph-20241107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:34:35.766023+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21a8cfeac2","claim":"Craig Johnson was appointed as Director at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"Effective November 7, 2024, Aurinia issued a press release announcing the appointment of Craig Johnson to the Board of Directors of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000106/0001600620-24-000106-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"2d8845e400","claim":"Scott Habig was terminated as Chief Commercial Officer at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"Aurinia plans to terminate its employment relationship with Scott Habig.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000106/0001600620-24-000106-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"},{"claim_id":"5ba929bb36","claim":"Dr. Robert T. Foster retired as Director at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"the Company also announced that Dr. Robert T. Foster has retired from the Board effective November 5, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000106/0001600620-24-000106-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8c2383f229a0de074531db04e4a0726b8de24664","claim":"Aurinia Pharmaceuticals Inc. announced a restructuring with charges of $15 to $19 million affecting the Company (approximately 45%).","evidence_excerpt":"cash equivalents, restricted cash, and investments of $348.7 million as of September 30, 2024 • Anticipates a one-time restructuring charge in the fourth quarter of 2024 of $15 to $19 million and estimates post-restructuring annualized cash-based operating expense savings of more than $40 million • Reiterates 2024 net product revenue guidance range of","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062024000106/0001600620-24-000106-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"$15 to $19 million"},{"label":"Affected area","value":"the Company"},{"label":"Headcount","value":"approximately 45%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}